Oricell Therapeutics secured $110 million to expand its cell therapy platform aimed at GPC3-positive liver cancers, where there are currently no FDA-approved therapies. The company positions its approach as a potential best-in-class option within a competitive landscape that includes AstraZeneca and Eureka Therapeutics. The financing supports clinical development activities and program scaling as Oricell works to differentiate its product against incumbents and platform peers. For the sector, the round signals continued investor appetite for next-generation cell therapy targeting solid-tumor surface antigens, particularly where unmet need remains high and current standard therapies are limited. The GPC3 focus also highlights how developers are pursuing “precision oncology” strategies that combine tumor selectivity with immunobiology designed to improve penetration and persistence in solid tumors.